Design, synthesis, and antitumor activities of novel ureido/thioureido derivatives with a 4-phenylthiazol-2-amine scaffold

Hepatocellular carcinoma (HCC) presents a significant global health challenge, necessitating the exploration of novel chemical entities or innovative therapeutic approaches targeting diverse signaling mechanisms. In this study, our focus was on developing a series of ureido/thioureido derivatives with a 4-phenylthiazol-2-amine scaffold to design structurally innovative candidates for HCC treatment, drawing inspiration from the structural characteristics of type II inhibitors like Sorafenib. The synthesized compounds underwent comprehensive evaluation for their antiproliferative activities against human MCF7, HepG2, QGY7703, SMMC-7721, Huh-7, and PLC cells. Additionally, investigations into the molecular targets of selected compounds were conducted. Notably, compound 31 emerged as a standout performer, displaying an IC₅₀ of 0.94 ± 0.29 μM against HepG2 cells, surpassing the efficacy of Sorafenib (1.62 ± 0.27 μM). Further investigations revealed its capability for G2/M phase arrest, apoptosis induction, and significant inhibition of cell cloning and migration in HepG2 cells. Moreover, compound 31 exhibited a notable positive effect on IGF1R, with a significant inhibitory activity of 69.22 % at a concentration of 10 μM. Molecular docking analyses revealed a stronger affinity between compound 31 and the receptor compared to the IGF1R inhibitor OZN2290. In conclusion, compound 31 emerges as a promising candidate for HCC treatment.